drugset / Trial / NCT00003705
BMS-184476 in Treating Patients With Advanced Solid Tumors
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-184476 in treating patients who have advanced solid tumors.
Timeline
- Start
- 1997-11
- Primary completion
- —
- Completion
- —
Publications
- Background Plummer R, Ghielmini M, Calvert P, Voi M, Renard J, Gallant G, Gupta E, Calvert H, Sessa C. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res. 2002 Sep;8(9):2788-97.
- Results Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol. 2001 May 1;19(9):2493-503. doi: 10.1200/JCO.2001.19.9.2493.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-184476 | Small molecule | 20 mg/m2 | Intravenous |
| Subject | BMS-184476 | Small molecule | 40 mg/m2 | Intravenous |
| Subject | BMS-184476 | Small molecule | 60 mg/m2 | Intravenous |
| Subject | BMS-184476 | Small molecule | 70 mg/m2 | Intravenous |
| Subject | BMS-184476 | Small molecule | 80 mg/m2 | Intravenous |